About BeiGene
BeiGene is a company based in Cambridge (United States) founded in 2010 by John V Oyler. BeiGene has raised $172 million across 6 funding rounds from investors including Merck, Amgen and Fidelity Investments. BeiGene offers products and services including Cancer Therapies. BeiGene operates in a competitive market with competitors including Moderna, Incyte, Vir Biotechnology, Regeneron Pharmaceuticals and MorphoSys, among others.
- Headquarter Cambridge, United States
- Founders John V Oyler
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Beigene, Ltd.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$172 M (USD)
in 6 rounds
-
Latest Funding Round
$2.1 B (USD), Post-IPO
Jul 15, 2020
-
Investors
Merck
& 9 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of BeiGene
BeiGene offers a comprehensive portfolio of products and services, including Cancer Therapies.
Develops treatments for hematology and solid tumors via clinical trials
People of BeiGene
Unlock access to complete
Unlock access to complete
Leadership Team
134 people
Software Development Team
103 people
Operations Team
50 people
Senior Team
49 people
Human Resources and Administration
23 people
Finance and Accounting
20 people
Product Management Team
12 people
Global Team
11 people
Unlock access to complete
Funding Insights of BeiGene
BeiGene has successfully raised a total of $172M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $2.1 billion completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $2.1B
- First Round First Round
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2020 | Amount | Post-IPO - BeiGene | Valuation |
investors |
|
| Oct, 2019 | Amount | Post-IPO - BeiGene | Valuation |
investors |
|
| May, 2015 | Amount | Series B - BeiGene | Valuation | Hillhouse |
Investors in BeiGene
BeiGene has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, Amgen and Fidelity Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location | |
|
Global private equity investments are managed with long-term focus.
|
Founded Year | Domain | Location | |
|
Acquisitions are targeted by CPE as a private equity firm.
|
Founded Year | Domain | Location |
Investments & Acquisitions by BeiGene
Financial Statements - BeiGene
Beigene Comparisons
Competitors of BeiGene
BeiGene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Incyte, Vir Biotechnology, Regeneron Pharmaceuticals and MorphoSys, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
Frequently Asked Questions about BeiGene
BeiGene was founded in 2010 and raised its 1st funding round 1 year after it was founded.
BeiGene is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
John V Oyler is the current CEO of BeiGene. They have also founded this company.
BeiGene is a funded company, having raised a total of $172M across 6 funding rounds to date. The company's 1st funding round was a Series B of $97M, raised on May 02, 2011.
Developer of targeted and immune-oncology drugs against cancer. The companys product pipeline includes oral small molecule inhibitors and monoclonal antibodies, such as BGB-3111, an oral inhibitor of Bruton tyrosine kinase, BGB-283, a B-RAF inhibitor; and BGB-290, a poly (ADP-ribose) polymerase inhibitor. Also, has another candidate BGB-108, a potentially differentiated PD-1 monoclonal antibody candidate.
BeiGene's top competitors include Moderna, Regeneron Pharmaceuticals and Annexon.
BeiGene offers Cancer Therapies.
BeiGene has 10 investors. Key investors include Merck, Amgen, Fidelity Investments, T. Rowe Price, and Rock Springs Capital.